Industry-Leading Discovery and Clinical Assets

Programs & Assets
Discovery/Preclinical → IND-enabling
Phase 1
Phase 2
Phase 3
NDA filing
Key Milestones
Inflammation and Immunology
Icotrokinra
Oral IL-23R
Peptide Antagonist

Moderate-to-Severe Psoriasis
ICONIC-LEAD Ph3 completed**, ICONIC-TOTAL Ph3 completed**
• Psoriasis NDA (US)/MAA (EU) submitted
ICONIC-ADVANCE-1&2 Ph3 completed**, ICONIC-ASCEND Ph3 ongoing
• Superiority of icotrokinra vs. deucravacitinib achieved; study of icotrokinra vs ustekinumab initiated
Psoriatic Arthritis
ICONIC PsA-1 & -2 Ph3 ongoing
Ulcerative Colitis
ANTHEM-UC Ph2b completed**; ICONIC-UC Ph3 initiated
• ICONIC-UC initiated Q4 ‘25
Crohn’s Disease
ICONIC-CD Ph 2/3 initiated
• ICONIC-CD initiated Q4 ‘25
PN-881*
Oral IL-17 Antagonist
Psoriasis, Psoriatic Arthritis, Hidradenitis Suppurativa, Spondyloarthritis
Ph1 initiated
• Phase 1 initiated Q4 ‘25
Hematology
Rusfertide
SC Hepcidin Mimetic

Polycythemia Vera
REVIVE Ph2 & PACIFIC Ph2 completed***, VERIFY Ph3 completed**, THRIVE Ph2 ongoing
• NDA filing EOY ’25
• ASCO ’25 plenary session
Oral Hepcidin*
Polycythemia Vera, Hereditary Hemochromatosis, Other
Pre-clinical
• Development candidate Q4 ‘25
Metabolic
PN-477sc*
PN-477oral*
GLP-1, GIP,and GCP Agonist
Obesity & Associated Co-Morbidities
IND-Enabling Studies
•
PN-477sc Phase 1 initiation Mid ‘26
IND-Enabling Studies
• PN-477oral Phase 1 initiation 2H ‘26

*Fully owned by Protagonist Therapeutics, Inc.; **Primary endpoint completed; ***Study completed.